Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, ...
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) is a clinical-stage biopharmaceutical company headquartered in Berkeley Heights, New Jersey, dedicated to developing and commercializing innovative therapies for prevalent retinal diseases. The company was founded in 2019 by experienced leaders in ophthalmology, including scientific co-founder Dr. Napoleone Ferrara, a pioneer in VEGF research. Kalaris' ...Kalaris Therapeutics, Inc. (NASDAQ: KLRS) is a clinical-stage biopharmaceutical company headquartered in Berkeley Heights, New Jersey, dedicated to developing and commercializing innovative therapies for prevalent retinal diseases. The company was founded in 2019 by experienced leaders in ophthalmology, including scientific co-founder Dr. Napoleone Ferrara, a pioneer in VEGF research. Kalaris' lead product candidate, TH103, is an engineered anti-vascular endothelial growth factor (VEGF) drug designed to provide increased and longer-lasting efficacy compared to existing treatments. TH103 is being developed for neovascular age-related macular degeneration (nAMD) and other exudative and neovascular retinal diseases, representing a significant unmet medical need. As a clinical-stage company, Kalaris has not yet generated revenue, and its financial focus is on research and development, with an emphasis on advancing TH103 through clinical trials. The company's financial metrics reflect its pre-revenue status, with negative operating cash flow and profitability ratios, but it maintains a strong cash position to fund operations. Kalaris was formerly AlloVir, Inc., and underwent a strategic merger and reverse merger to become Kalaris Therapeutics. The company is led by President and CEO Andrew Oxtoby, who has been instrumental in guiding the company's strategic direction. With a small team of approximately 20 employees, Kalaris is poised to make significant contributions to the field of retinal disease treatment, aiming to improve patient outcomes and quality of life. The company's website is kalaristx.com, and it is publicly traded on the NASDAQ Global Market.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-43.4M
+26.1%
-6.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-43.2M
+36.2%
+14.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
1.8%
—
+18.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
12.23x
-45.9%
-9.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
